You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,233,959


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,233,959
Title:Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Inventor(s): Sommer; Andreas (Carlsbad, CA), Zhang; Chengzhi (San Diego, CA), Carter; John (Vista, CA), Arthur; John (Vista, CA), Bradbury; Margaret (Vista, CA), Gant; Thomas (Carlsbad, CA), Shahbaz; Manouchehr (San Diego, CA)
Assignee: Auspex Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:14/479,823
Patent Claims: 1. A pharmaceutical composition comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2% and about 18% of d.sub.6-tetrabenazine; between about 60% and about 70% mannitol; between about 15% and about 25% microcrystalline cellulose; between about 1% and about 10% of a polyvinylpyrrolidone; between about 0.5% and about 2% of a polysorbate; between about 5% and about 20% of a poly(ethylene oxide) polymer; and between about 0.5% and about 2% of magnesium stearate.

2. The pharmaceutical composition as recited in claim 1 wherein said polyvinylpyrrolidone has an average molecular weight of about 58,000 and a K-value of 29 to 32.

3. The pharmaceutical composition as recited in claim 1 wherein said polysorbate is polyoxyethylene (20) sorbitan monooleate.

4. The pharmaceutical composition as recited in claim 1 wherein said poly(ethylene oxide) polymer is poly(ethylene) oxide polymer PEG-45M.

5. The pharmaceutical composition as recited in claim 1 further comprising an anti-oxidant.

6. The pharmaceutical composition as recited in claim 5 wherein said anti-oxidant is selected from the group consisting of butylated hydroxyanisole and butylated hydroxytoluene.

7. The pharmaceutical composition as recited in claim 1 further comprising an aqueous film coating.

8. The pharmaceutical composition as recited in claim 7 wherein said aqueous film coating comprises polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a FD&C color additive.

9. The pharmaceutical composition as recited in claim 1 wherein the total weight is about 350 mg.

10. The pharmaceutical composition as recited in claim 1 comprising from about 5 mg to about 30 mg of d.sub.6-tetrabenazine.

11. The pharmaceutical composition as recited in claim 10 comprising about 6 mg of d.sub.6-tetrabenazine.

12. The pharmaceutical composition as recited in claim 10 comprising about 12 mg of d.sub.6-tetrabenazine.

13. The pharmaceutical composition as recited in claim 10 comprising about 15 mg of d.sub.6-tetrabenazine.

14. The pharmaceutical composition as recited in claim 10 comprising about 18 mg of d.sub.6-tetrabenazine.

15. The pharmaceutical composition as recited in claim 1 comprising, in a solid dosage form for oral delivery of about 350 mg total weight: about 15 milligrams d.sub.6-tetrabenazine; about 62.0% mannitol; about 17.7% microcrystalline cellulose; about 4.0% of polyvinylpyrrolidine having an average molecular weight of about 58,000 and a K-value of 29 to 32; about 1.1% of polyoxyethylene (20) sorbitan monooleate; about 10.0% of poly(ethylene) oxide polymer PEG-45M; and about 1.0% of magnesium stearate.

16. The pharmaceutical composition as recited in claim 15 further comprising an anti-oxidant selected from the group consisting of butylated hydroxyanisole and butylated hydroxytoluene.

17. The pharmaceutical composition as recited in claim 16 further comprising an aqueous film coating.

18. The pharmaceutical composition as recited in claim 17 wherein said aqueous film coating comprises polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a FD&C color additive.

19. The pharmaceutical composition as recited in claim 1 comprising, in a solid dosage form for oral delivery of about 350 mg total weight: about 6 milligrams d.sub.6-tetrabenazine; about 63.6% mannitol; about 18.3% microcrystalline cellulose; about 4.0% of polyvinylpyrrolidine having an average molecular weight of about 58,000 and a K-value of 29 to 32; about 1.1% of polyoxyethylene (20) sorbitan monooleate; about 10.0% of poly(ethylene) oxide polymer PEG-45M; about 1.0% of magnesium stearate; about 0.1% of butylated hydroxyanisole; and about 0.1% of butylated hydroxytoluene.

20. The pharmaceutical composition as recited in claim 19 further comprising an aqueous film coating.

21. The pharmaceutical composition as recited in claim 20 wherein said aqueous film coating comprises polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a FD&C color additive.

22. The pharmaceutical composition as recited in claim 1 comprising, in a solid dosage form for oral delivery of about 350 mg total weight: about 12 milligrams d.sub.6-tetrabenazine; about 62.3% mannitol; about 17.9% microcrystalline cellulose; about 4.0% of polyvinylpyrrolidine having an average molecular weight of about 58,000 and a K-value of 29 to 32; about 1.1% of polyoxyethylene (20) sorbitan monooleate; about 10.0% of poly(ethylene) oxide polymer PEG-45M; about 1.0% of magnesium stearate; about 0.1% of butylated hydroxyanisole; and about 0.1% of butylated hydroxytoluene.

23. The pharmaceutical composition as recited in claim 22 further comprising an aqueous film coating.

24. The pharmaceutical composition as recited in claim 23 wherein said aqueous film coating comprises polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a FD&C color additive.

25. The pharmaceutical composition as recited in claim 1 comprising, in a solid dosage form for oral delivery of about 350 mg total weight: about 18 milligrams d.sub.6-tetrabenazine; about 60.5% mannitol; about 18.0% microcrystalline cellulose; about 4.0% of polyvinylpyrrolidine having an average molecular weight of about 58,000 and a K-value of 29 to 32; about 1.1% of polyoxyethylene (20) sorbitan monooleate; about 10.0% of poly(ethylene) oxide polymer PEG-45M; about 1.0% of magnesium stearate; about 0.1% of butylated hydroxyanisole; and about 0.1% of butylated hydroxytoluene.

26. The pharmaceutical composition as recited in claim 25 further comprising an aqueous film coating.

27. The pharmaceutical composition as recited in claim 26 wherein said aqueous film coating comprises polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a FD&C color additive.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.